T1	Pharmacological_substance 54 88	lipiodol soluble anti-cancer agent
T3	Disorder 203 227	hepatocellular carcinoma
N1 	Reference T3 UMLS:C2239176	hepatocellular carcinoma
T5	Disorder 379 403	hepatocellular carcinoma
N2 	Reference T5 UMLS:C2239176	hepatocellular carcinoma
T6	Disorder 405 408	HCC
N3 	Reference T6 UMLS:C2239176	HCC
T7	Disorder 426 448	cirrhosis of the liver
N4 	Reference T7 UMLS:C0023890	cirrhosis of the liver
T17	Disorder 1018 1023	fever
N5 	Reference T17 UMLS:C0015967	fever
T18	Disorder 1025 1039	localized pain
N6 	Reference T18 UMLS:C0520962	localized pain
T19	Disorder 1063 1080	liver dysfunction
N7 	Reference T19 UMLS:C0086565	liver dysfunction
T20	Pharmacological_substance 118 126	lipiodol
N1000 	Reference T20 MeSH:D004998	lipiodol
T2	Subject 362 373	20 patients
T4	Disorder 1041 1058	myelo-suppression
N8 	Reference T4 UMLS:C0854467	myelo-suppression
T8	Pharmacological_substance 89 95	SMANCS
N1001 	Reference T8 MeSH:C035755	SMANCS
T9	Pharmacological_substance 100 103	ADR
N1002 	Reference T9 MeSH:D004317	ADR
T11	Pharmacological_substance 460 485	oily carcinostatic agents
T12	Pharmacological_substance 264 266	Lp
N1003 	Reference T12 MeSH:D004998	Lp
T13	Pharmacological_substance 507 509	Lp
N1004 	Reference T13 MeSH:D004998	Lp
T14	Pharmacological_substance 719 721	Lp
N1005 	Reference T14 MeSH:D004998	Lp
T15	Pharmacological_substance 790 792	Lp
N1006 	Reference T15 MeSH:D004998	Lp
T16	Pharmacological_substance 833 835	Lp
N1007 	Reference T16 MeSH:D004998	Lp
T21	Pharmacological_substance 920 922	Lp
N1008 	Reference T21 MeSH:D004998	Lp
T22	Pharmacological_substance 979 981	Lp
N1009 	Reference T22 MeSH:D004998	Lp
T25	Speculation_cue 349 358	evaluated
